CSF3 and cancer: It is recommended that pegfilgrastim be administered 24–72 h after chemotherapy according to the clinical practice guidelines of the American Society of Clinical Oncology (ASCO),10 the National Comprehensive Cancer Network (NCCN),11 and the European Organization for Research and Treatment of Cancer (EORTC),12 because the administration of G‐CSF at earlier times may increase myelosuppression.